Your browser doesn't support javascript.
loading
Beneficial tyrosine kinase inhibitor therapy in a patient with relapsed BCR-ABL1-like acute lymphoblastic leukemia with CCDC88C-PDGFRB fusion.
Oya, Shuki; Morishige, Satoshi; Ozawa, Hidetoshi; Sasaki, Kensuke; Semba, Yuichiro; Yamasaki, Yoshitaka; Nakamura, Takayuki; Aoyama, Kazutoshi; Seki, Ritsuko; Mouri, Fumihiko; Osaki, Koichi; Miyamoto, Toshihiro; Maeda, Takahiro; Nagafuji, Koji.
Afiliação
  • Oya S; Division of Hematology and Oncology, Department of Medicine, Kurume University School of Medicine, 67 Asahi-machi, Kurume, 830-0011, Japan.
  • Morishige S; Division of Hematology and Oncology, Department of Medicine, Kurume University School of Medicine, 67 Asahi-machi, Kurume, 830-0011, Japan.
  • Ozawa H; Division of Hematology and Oncology, Department of Medicine, Kurume University School of Medicine, 67 Asahi-machi, Kurume, 830-0011, Japan.
  • Sasaki K; Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, Fukuoka, 812-8582, Japan.
  • Semba Y; Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, Fukuoka, 812-8582, Japan.
  • Yamasaki Y; Division of Hematology and Oncology, Department of Medicine, Kurume University School of Medicine, 67 Asahi-machi, Kurume, 830-0011, Japan.
  • Nakamura T; Division of Hematology and Oncology, Department of Medicine, Kurume University School of Medicine, 67 Asahi-machi, Kurume, 830-0011, Japan.
  • Aoyama K; Division of Hematology and Oncology, Department of Medicine, Kurume University School of Medicine, 67 Asahi-machi, Kurume, 830-0011, Japan.
  • Seki R; Division of Hematology and Oncology, Department of Medicine, Kurume University School of Medicine, 67 Asahi-machi, Kurume, 830-0011, Japan.
  • Mouri F; Division of Hematology and Oncology, Department of Medicine, Kurume University School of Medicine, 67 Asahi-machi, Kurume, 830-0011, Japan.
  • Osaki K; Division of Hematology and Oncology, Department of Medicine, Kurume University School of Medicine, 67 Asahi-machi, Kurume, 830-0011, Japan.
  • Miyamoto T; Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, Fukuoka, 812-8582, Japan.
  • Maeda T; Center for Cellular and Molecular Medicine, Kyushu University Hospital, Fukuoka, 812-8582, Japan.
  • Nagafuji K; Division of Hematology and Oncology, Department of Medicine, Kurume University School of Medicine, 67 Asahi-machi, Kurume, 830-0011, Japan. knagafuji@med.kurume-u.ac.jp.
Int J Hematol ; 113(2): 285-289, 2021 Feb.
Article em En | MEDLINE | ID: mdl-32951102
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Proteínas de Fusão Oncogênica / Receptor beta de Fator de Crescimento Derivado de Plaquetas / Peptídeos e Proteínas de Sinalização Intracelular / Inibidores de Proteínas Quinases / Leucemia-Linfoma Linfoblástico de Células Precursoras / Proteínas dos Microfilamentos Tipo de estudo: Diagnostic_studies / Prognostic_studies Limite: Adult / Female / Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Proteínas de Fusão Oncogênica / Receptor beta de Fator de Crescimento Derivado de Plaquetas / Peptídeos e Proteínas de Sinalização Intracelular / Inibidores de Proteínas Quinases / Leucemia-Linfoma Linfoblástico de Células Precursoras / Proteínas dos Microfilamentos Tipo de estudo: Diagnostic_studies / Prognostic_studies Limite: Adult / Female / Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article